

Author Index Volume 2 (2015)

The issue number is given in front of the pagination

- Abicht, A., see Ørstavik, K. (2) 181–184
- Accorsi, A., T. Mehuron, A. Kumar, Y. Rhee and M. Girgenrath, Integrin dysregulation as a possible driver of matrix remodeling in Laminin-deficient congenital muscular dystrophy (MDC1A) (1) 51–61
- Alexander, M.S. and L.M. Kunkel, “Skeletal Muscle MicroRNAs: Their Diagnostic and Therapeutic Potential in Human Muscle Diseases” (1) 1–11
- Allamand, V., see Nelson, I. (3) 229–240
- Allen, P., see Cacheux, M. (4) 421–432
- Allenbach, Y. and O. Benveniste, Diagnostic Utility of Auto-Antibodies in Inflammatory Muscle Diseases (1) 13–25
- Alston, C.L., see Wesolowska, M. (4) 409–419
- Al-Zaidy, S.A., Z. Sahenk, L.R. Rodino-Klapac, B. Kaspar and J.R. Mendell, Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy (3) 185–192
- Ander, B.P., see Liu, D.Z. (4) 387–396
- Annoussamy, M., see Servais, L. (3) 269–279
- Apponi, L.H., see Vest, K.E. (4) 439–446
- Azzi, V., see Catteruccia, M. (4) 453–462
- Babuty, D., see Nelson, I. (3) 229–240
- Banerjee, A., see Vest, K.E. (4) 439–446
- Barnett, C., I.S.J. Merkies, H. Katzberg and V. Bril, Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale (3) 301–311
- Barnett, C., see Kassardjian, C.D. (1) 93–97
- Barthélémy, F., C. Blouin, N. Wein, V. Mouly, S. Courrier, E. Dionnet, V. Kergourlay, Y. Mathieu, L. Garcia, G. Butler-Browne, C. Lamaze, N. Lévy, M. Krahn and M. Bartoli, Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients’ Cells (3) 281–290
- Bartoli, M., see Barthélémy, F. (3) 281–290
- Bartoli, M., see Cerino, M. (2) 131–136
- Bates, M.G., see Newman, J. (2) 151–155
- Battle, D., see Renusch, S.R. (2) 119–130
- Bécane, H.-M., see Nelson, I. (3) 229–240
- Beggs, A.H., see Ceyhan-Birsoy, O. (1) 87–92
- Béhin, A., see Cerino, M. (2) 131–136
- Bell, C.F., see Landfeldt, E. (1) 63–72
- Bennett, D., see Burch, P.M. (3) 241–255
- Benveniste, O., see Allenbach, Y. (1) 13–25
- Bernard, R., see Cerino, M. (2) 131–136
- Béroud, C., see Nelson, I. (3) 229–240
- Bertini, E., see Catteruccia, M. (4) 453–462
- Beuvin, M., see Malfatti, E. (3) 219–227
- Biancalana, V. and J. Laporte, Diagnostic use of Massively Parallel Sequencing in Neuromuscular Diseases: Towards an Integrated Diagnosis (3) 193–203
- Blouin, C., see Barthélémy, F. (3) 281–290
- Blum, A., see Cacheux, M. (4) 421–432
- Böhm, J., see Malfatti, E. (3) 219–227
- Bonne, G., see Nelson, I. (3) 229–240
- Bouchet-Séraphin, C., S. Vuillaumier-Barrot and N. Seta, Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein (1) 27–38
- Breton, R., see Denicourt, M. (1) 99–105
- Bril, V., see Barnett, C. (3) 301–311
- Bril, V., see Kassardjian, C.D. (1) 93–97
- Brocard, J., see Cacheux, M. (4) 421–432
- Brochier, G., see Malfatti, E. (3) 219–227
- Brochier, G., see Richard, P. (2) 175–180
- Browne, G.B., see Thorley, M. (3) 205–217
- Burch, P.M., O. Pogoryelova, R. Goldstein, D. Bennett, M. Guglieri, V. Straub, K. Bushby, H. Lochmüller and C. Morris, Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy (3) 241–255
- Bushby, K., see Burch, P.M. (3) 241–255
- Bushby, K., see Landfeldt, E. (1) 63–72
- Butler-Browne, G., see Barthélémy, F. (3) 281–290
- Butoianu, N., see Servais, L. (3) 269–279
- Cacheux, M., A. Blum, M. Sébastien, A.S. Wozny, J. Brocard, K. Mamchaoui, V. Mouly, N. Roux-Buisson, J. Rendu, N. Monnier, R. Krivosic, P.

- Allen, A. Lacour, J. Lunardi, J. Fauré and I. Marty, Functional Characterization of a Central Core Disease RyR1 Mutation (p.Y4864H) Associated with Quantitative Defect in RyR1 Protein (4) 421–432
- Campbell, C., see Wei, Y. (3) 313–324
- Cances, C., see Servais, L. (3) 269–279
- Carr, B., see Montes, J. (4) 463–470
- Catteruccia, M., C. Vuillerot, I. Vaugier, D. Leclair, V. Azzi, L. Viollet, B. Estournet, E. Bertini and S. Quijano-Roy, Orthopedic Management of Scoliosis by Garches Brace and Spinal Fusion in SMA Type 2 Children (4) 453–462
- Cerino, M., S. Gorokhova, A. Béhin, J.A. Urtizbera, V. Kergourlay, E. Salvo, R. Bernard, N. Lévy, M. Bartoli and M. Krahn, Novel Pathogenic Variants in a French Cohort Widen the Mutational Spectrum of GNE Myopathy (2) 131–136
- Ceyhan-Birsoy, O., B. Talim, L.C. Swanson, M. Karakaya, M.A. Graff, A.H. Beggs and H. Topaloglu, Whole Exome Sequencing Reveals *DYSF*, *FKTN*, and *ISPD* Mutations in Congenital Muscular Dystrophy Without Brain or Eye Involvement (1) 87–92
- Chadwick, J.A., see Lowe, J. (3) 257–268
- Chen, W., see Johnson, N.E. (4) 447–452
- Chinnery, P.F., see Wesolowska, M. (4) 409–419
- Chrzanowska-Lightowlers, Z.M., see Wesolowska, M. (4) 409–419
- Ciafaloni, E., see Johnson, N.E. (4) 447–452
- Corbett, A.H., see Vest, K.E. (4) 439–446
- Courrier, S., see Barthélémy, F. (3) 281–290
- Cruz, R., see Montes, J. (4) 463–470
- Cuisset, J.-M., see Servais, L. (3) 269–279
- de Groot, I.J.M., see van den Engel-Hoek, L. (4) 357–369
- De Luca, A., see Willmann, R. (2) 113–117
- de Swart, B.J.M., see van den Engel-Hoek, L. (4) 357–369
- De Vivo, D.C., see Montes, J. (4) 463–470
- Deenen, J.C.W., C.G.C. Horlings, J.J.G.M. Verschuuren, A.L.M. Verbeek and B.G.M. van Engelen, The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature (1) 73–85
- Delmont, E. and H. Willison, Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders (2) 107–112
- Delmont, E., see Galban-Horcajo, F. (2) 157–165
- Demay, L., see Richard, P. (2) 175–180
- Denicourt, M., M.T. Pham, J. Mathieu and R. Breton, DM1 Patients with Small CTG Expansions are also at Risk of Severe Conduction Abnormalities (1) 99–105
- Dionnet, E., see Barthélémy, F. (3) 281–290
- Duan, D., see Hakim, C.H. (4) 397–407
- Duddy, W., see Thorley, M. (3) 205–217
- Duguez, S., see Thorley, M. (3) 205–217
- Dunaway, S., see Montes, J. (4) 463–470
- Elsheikh, B.H., see Rensch, S.R. (2) 119–130
- Erasmus, C.E., see van den Engel-Hoek, L. (4) 357–369
- Estournet, B., see Catteruccia, M. (4) 453–462
- Eymard, B., see Nelson, I. (3) 229–240
- Eymard, B., see Richard, P. (2) 175–180
- Fardeau, M., see Richard, P. (2) 175–180
- Fauré, J., see Cacheux, M. (4) 421–432
- Feng, F., see Hakim, C.H. (4) 397–407
- Ferrer-Monasterio, X., see Richard, P. (2) 175–180
- Floyd, K.T., see Lowe, J. (3) 257–268
- Freitas, M.A., see Rensch, S.R. (2) 119–130
- Fricke, A.F., see Statland, J.M. (3) 291–299
- Galban-Horcajo, F., L. Vlam, E. Delmont, S.K. Halstead, L. van den Berg, W-L. van der Pol and H.J. Willison, The Diagnostic Utility of Determining Anti-GM1: GalC Complex Antibodies in Multifocal Motor Neuropathy: A Validation Study (2) 157–165
- Galna, B., see Newman, J. (2) 151–155
- Garber, C.E., see Montes, J. (4) 463–470
- Garcia, L., see Barthélémy, F. (3) 281–290
- Gardner, B.B., K.A. Swaggart, G. Kim, S. Watson and E.M. McNally, Cardiac function in muscular dystrophy associates with abdominal muscle pathology (1) 39–49
- Gidaro, T., see Richard, P. (2) 175–180
- Gidaro, T., see Servais, L. (3) 269–279
- Girgenrath, M., see Accorsi, A. (1) 51–61
- Goldstein, R., see Burch, P.M. (3) 241–255
- Gorman, G.S., see Newman, J. (2) 151–155
- Gorman, G.S., see Wesolowska, M. (4) 409–419
- Gorokhova, S., see Cerino, M. (2) 131–136
- Graff, M.A., see Ceyhan-Birsoy, O. (1) 87–92
- Griffin, H., see Wesolowska, M. (4) 409–419
- Guglieri, M., see Burch, P.M. (3) 241–255
- Guglieri, M., see Landfeldt, E. (1) 63–72
- Hagerman, K.A., see Johnson, N.E. (4) 447–452
- Hakim, C.H., A.A. Peters, F. Feng, G. Yao and D.

- Duan, Night Activity Reduction is a Signature Physiological Biomarker for Duchenne Muscular Dystrophy Dogs (4) 397–407
- Halicek, M.T., see Pfohl, S.R. (2) 137–150
- Halstead, S.K., see Galban-Horcajo, F. (2) 157–165
- Harshman, S., see Rensch, S.R. (2) 119–130
- He, L., see Wesolowska, M. (4) 409–419
- Heatwole, C.R., see Johnson, N.E. (4) 447–452
- Henderson, D., see Statland, J.M. (3) 291–299
- Hogrel, J.-Y., see Servais, L. (3) 269–279
- Horlings, C.G.C., see Deenen, J.C.W. (1) 73–85
- Hotta, A., Genome Editing Gene Therapy for Duchenne Muscular Dystrophy (4) 343–355
- Hu, S., see Liu, D.Z. (4) 387–396
- Hung, M., see Johnson, N.E. (4) 447–452
- Hyzewicz, J., U.T. Ruegg and S. Takeda, Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients (4) 325–342
- Jakovljevic, D.G., see Newman, J. (2) 151–155
- Janssen, P.M.L., see Lowe, J. (3) 257–268
- Jewell, D., see Kassardjian, C.D. (1) 93–97
- Jickling, G.C., see Liu, D.Z. (4) 387–396
- Johnson, N.E., M. Hung, E. Nasser, K.A. Hagerman, W. Chen, E. Ciafaloni and C.R. Heatwole, The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study (4) 447–452
- Kamil-Rosenberg, S., see Montes, J. (4) 463–470
- Karakaya, M., see Ceyhan-Birsoy, O. (1) 87–92
- Kaspar, B., see Al-Zaidy, S.A. (3) 185–192
- Kassardjian, C.D., S. Kokokyi, C. Barnett, D. Jewell, V. Bril, B.J. Murray and H.D. Katzberg, Excessive Daytime Sleepiness in Patients with Myasthenia Gravis (1) 93–97
- Katzberg, H., see Barnett, C. (3) 301–311
- Katzberg, H.D., see Kassardjian, C.D. (1) 93–97
- Kergourlay, V., see Barthélémy, F. (3) 281–290
- Kergourlay, V., see Cerino, M. (2) 131–136
- Kerty, E., see Ørstavik, K. (2) 181–184
- Kiiski, K., V-L. Lehtokari, A.Y. Manzur, C. Sewry, I. Zaharieva, F. Muntoni, K. Pelin and C. Wallgren-Pettersson, A Large Deletion Affecting *TPM3*, Causing Severe Nemaline Myopathy (4) 433–438
- Kim, G., see Gardner, B.B. (1) 39–49
- Kissel, J.T., see Rensch, S.R. (2) 119–130
- Klein, A., see Servais, L. (3) 269–279
- Kokokyi, S., see Kassardjian, C.D. (1) 93–97
- Kolb, S.J., see Rensch, S.R. (2) 119–130
- Krahn, M., see Barthélémy, F. (3) 281–290
- Krahn, M., see Cerino, M. (2) 131–136
- Kramer, S.S., see Montes, J. (4) 463–470
- Krivosic, R., see Cacheux, M. (4) 421–432
- Kumar, A., see Accorsi, A. (1) 51–61
- Kunkel, L.M., see Alexander, M.S. (1) 1–11
- Lacène, E., see Malfatti, E. (3) 219–227
- Lacour, A., see Cacheux, M. (4) 421–432
- Laforêt, P., see Richard, P. (2) 175–180
- Lamaze, C., see Barthélémy, F. (3) 281–290
- Landfeldt, E., P. Lindgren, C.F. Bell, C. Schmitt, M. Guglieri, V. Straub, H. Lochmüller and K. Bushby, Compliance to Care Guidelines for Duchenne Muscular Dystrophy (1) 63–72
- Laporte, J., see Biancalana, V. (3) 193–203
- Laporte, J., see Malfatti, E. (3) 219–227
- Laugel, V., see Servais, L. (3) 269–279
- Le Gall, L., see Thorley, M. (3) 205–217
- Le Guiner, C., see Servais, L. (3) 269–279
- Le Moing, A.-G., see Servais, L. (3) 269–279
- Leclair, D., see Catteruccia, M. (4) 453–462
- Lehtokari, V-L., see Kiiski, K. (4) 433–438
- Leturcq, F., see Nelson, I. (3) 229–240
- Leturcq, F., see Servais, L. (3) 269–279
- Lévy, N., see Barthélémy, F. (3) 281–290
- Lévy, N., see Cerino, M. (2) 131–136
- Li, X., see Rensch, S.R. (2) 119–130
- Lightowers, R.N., see Wesolowska, M. (4) 409–419
- Lindgren, P., see Landfeldt, E. (1) 63–72
- Liu, D.Z., B. Stamova, S. Hu, B.P. Ander, G.C. Jickling, X. Zhan, F.R. Sharp and B. Wong, MicroRNA and mRNA Expression Changes in Steroid Naïve and Steroid Treated DMD Patients (4) 387–396
- Lochmüller, H., see Burch, P.M. (3) 241–255
- Lochmüller, H., see Landfeldt, E. (1) 63–72
- Lowe, J., A.J. Wodarczyk, K.T. Floyd, N. Rastogi, E.J. Schultz, S.A. Swager, J.A. Chadwick, T. Tran, S.V. Raman, P.M.L. Janssen and J.A. Rafael-Fortney, The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy (3) 257–268
- Lunardi, J., see Cacheux, M. (4) 421–432
- Malatras, A., see Thorley, M. (3) 205–217
- Malfatti, E., J. Böhm, E. Lacène, M. Beuvin, G. Brochier, N.B. Romero and J. Laporte, A Premature Stop Codon in *MYO18B* is Associated with Severe Nemaline Myopathy with Cardiomyopathy (3) 219–227
- Malfatti, E., see Richard, P. (2) 175–180

- Mamchaoui, K., see Cacheux, M. (4) 421–432
 Manzur, A.Y., see Kiiski, K. (4) 433–438
 Martin-Négrier, M.-L., see Richard, P. (2) 175–180
 Marty, I., see Cacheux, M. (4) 421–432
 Mathieu, J., see Denicourt, M. (1) 99–105
 Mathieu, Y., see Barthélémy, F. (3) 281–290
 McFarland, R., see Newman, J. (2) 151–155
 McNally, E.M., see Gardner, B.B. (1) 39–49
 Mehuron, T., see Accorsi, A. (1) 51–61
 Mendell, J.R., see Al-Zaidy, S.A. (3) 185–192
 Merkies, I.S.J., see Barnett, C. (3) 301–311
 Miller, J.A.L., see Wesolowska, M. (4) 409–419
 Mitchell, C.S., see Pfohl, S.R. (2) 137–150
 Monnier, N., see Cacheux, M. (4) 421–432
 Montes, J., C.E. Garber, S.S. Kramer, M.J. Montgomery, S. Dunaway, S. Kamil-Rosenberg, B. Carr, R. Cruz, N.E. Strauss, D. Sproule and D.C. De Vivo, Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: Why are the Results Negative? (4) 463–470
 Montgomery, M.J., see Montes, J. (4) 463–470
 Montus, M., see Servais, L. (3) 269–279
 Moraux, A., see Servais, L. (3) 269–279
 Morris, C., see Burch, P.M. (3) 241–255
 Moullier, P., see Servais, L. (3) 269–279
 Mouly, V., see Barthélémy, F. (3) 281–290
 Mouly, V., see Cacheux, M. (4) 421–432
 Mouly, V., see Thorley, M. (3) 205–217
 Moyer, A.L. and K.R. Wagner, Mammalian *Mss51* is a Skeletal Muscle-Specific Gene Modulating Cellular Metabolism (4) 371–385
 MS Tomé, F., see Richard, P. (2) 175–180
 Muntoni, F., see Kiiski, K. (4) 433–438
 Murray, B.J., see Kassardjian, C.D. (1) 93–97
 Nagaraju, K., see Willmann, R. (2) 113–117
 Nasser, E., see Johnson, N.E. (4) 447–452
 Nelson, I., T. Stojkovic, V. Allamand, F. Leturcq, H.-M. Bécane, D. Babuty, A. Toutain, C. Bérout, P. Richard, N.B. Romero, B. Eymard, R.B. Yaou and G. Bonne, Laminin $\alpha 2$ Deficiency-Related Muscular Dystrophy Mimicking Emery-Dreifuss and Collagen VI related Diseases (3) 229–240
 Newman, J., B. Galna, D.G. Jakovljevic, M.G. Bates, A.M. Schaefer, R. McFarland, D.M. Turnbull, M.I. Trenell, R.W. Taylor, L. Rochester and G.S. Gorman, Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease (2) 151–155
 Odrzywolski, K.J., see Statland, J.M. (3) 291–299
 Ørstavik, K., S.C. Wallace, T. Torbergesen, A. Abicht, S.E. Tangsrud, E. Kerty and M. Rasmussen, A *de novo* Mutation in the *SCN4A* Gene Causing Sodium Channel Myotonia (2) 181–184
 Pajak, A., see Wesolowska, M. (4) 409–419
 Parthun, M.R., see Rensch, S.R. (2) 119–130
 Pavlath, G.K., see Vest, K.E. (4) 439–446
 Pelin, K., see Kiiski, K. (4) 433–438
 Peters, A.A., see Hakim, C.H. (4) 397–407
 Petri, H., see Werlauff, U. (2) 167–174
 Pfohl, S.R., M.T. Halicek and C.S. Mitchell, Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis (2) 137–150
 Pham, M.T., see Denicourt, M. (1) 99–105
 Pi, H., see Rensch, S.R. (2) 119–130
 Pogoryelova, O., see Burch, P.M. (3) 241–255
 Prior, T.W., see Rensch, S.R. (2) 119–130
 Pyle, A., see Wesolowska, M. (4) 409–419
 Quijano-Roy, S., see Catteruccia, M. (4) 453–462
 Rafael-Fortney, J.A., see Lowe, J. (3) 257–268
 Raman, S.V., see Lowe, J. (3) 257–268
 Rasmussen, M., see Ørstavik, K. (2) 181–184
 Rastogi, N., see Lowe, J. (3) 257–268
 Rendu, J., see Cacheux, M. (4) 421–432
 Rensch, S.R., S. Harshman, H. Pi, E. Workman, A. Wehr, X. Li, T.W. Prior, B.H. Elsheikh, K.J. Swoboda, L.R. Simard, J.T. Kissel, D. Battle, M.R. Parthun, M.A. Freitas and S.J. Kolb, Spinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults (2) 119–130
 Rhee, Y., see Accorsi, A. (1) 51–61
 Richard, P., C. Trollet, T. Gidaro, L. Demay, G. Brochier, E. Malfatti, F. MS Tomé, M. Fardeau, P. Laforêt, N. Romero, M.-L. Martin-Négrier, G. Solé, X. Ferrer-Monasterio, J.L. Saint-Guily and B. Eymard, *PABPNI* (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy – Consequences in Clinical Diagnosis and Genetic Counselling (2) 175–180
 Richard, P., see Nelson, I. (3) 229–240
 Rochester, L., see Newman, J. (2) 151–155
 Rodino-Klapac, L.R., see Al-Zaidy, S.A. (3) 185–192
 Romero, N., see Richard, P. (2) 175–180

- Romero, N.B., see Malfatti, E. (3) 219–227
 Romero, N.B., see Nelson, I. (3) 229–240
 Roux-Buisson, N., see Cacheux, M. (4) 421–432
 Rüegg, M.A., see Willmann, R. (2) 113–117
 Ruegg, U.T., see Hyzewicz, J. (4) 325–342
- Sabouraud, P., see Servais, L. (3) 269–279
 Sahenk, Z., see Al-Zaidy, S.A. (3) 185–192
 Saint-Guily, J.L., see Richard, P. (2) 175–180
 Salvo, E., see Cerino, M. (2) 131–136
 Schaefer, A.M., see Newman, J. (2) 151–155
 Schaefer, A.M., see Wesolowska, M. (4) 409–419
 Schmitt, C., see Landfeldt, E. (1) 63–72
 Schultz, E.J., see Lowe, J. (3) 257–268
 Sébastien, M., see Cacheux, M. (4) 421–432
 Seferian, A.M., see Servais, L. (3) 269–279
 Servais, L., M. Montus, C. Le Guiner, R.B. Yaou, M. Annoussamy, A. Moraux, J.-Y. Hogrel, A.M. Seferian, K. Zehrouni, A.-G. Le Moing, T. Gidaro, C. Vanhulle, V. Laugel, N. Butoianu, J.-M. Cuisset, P. Sabouraud, C. Cances, A. Klein, F. Leturcq, P. Moullier and T. Voit, Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype (3) 269–279
 Seta, N., see Bouchet-Séraphin, C. (1) 27–38
 Sewry, C., see Kiiski, K. (4) 433–438
 Shah, B., see Statland, J.M. (3) 291–299
 Sharp, F.R., see Liu, D.Z. (4) 387–396
 Simard, L.R., see Rensch, S.R. (2) 119–130
 Solé, G., see Richard, P. (2) 175–180
 Speechley, K., see Wei, Y. (3) 313–324
 Sproule, D., see Montes, J. (4) 463–470
 Stamova, B., see Liu, D.Z. (4) 387–396
 Statland, J.M., K.J. Odrzywolski, B. Shah, D. Henderson, A.F. Fricke, S. van der Maarel, S.J. Tapscott and R. Tawil, Immunohistochemical Characterization of Facioscapulohumeral Muscular Dystrophy Muscle Biopsies (3) 291–299
 Stojkovic, T., see Nelson, I. (3) 229–240
 Straub, V., see Burch, P.M. (3) 241–255
 Straub, V., see Landfeldt, E. (1) 63–72
 Strauss, N.E., see Montes, J. (4) 463–470
 Swager, S.A., see Lowe, J. (3) 257–268
 Swaggart, K.A., see Gardner, B.B. (1) 39–49
 Swanson, L.C., see Ceyhan-Birsoy, O. (1) 87–92
 Swoboda, K.J., see Rensch, S.R. (2) 119–130
- Takeda, S., see Hyzewicz, J. (4) 325–342
 Talim, B., see Ceyhan-Birsoy, O. (1) 87–92
 Tangsrud, S.E., see Ørstavik, K. (2) 181–184
 Tapscott, S.J., see Statland, J.M. (3) 291–299
 Tawil, R., see Statland, J.M. (3) 291–299
 Taylor, R.W., see Newman, J. (2) 151–155
 Taylor, R.W., see Wesolowska, M. (4) 409–419
 Thorley, M., A. Malatras, W. Duddy, L. Le Gall, V. Mouly, G.B. Browne and S. Duguez, Changes in Communication between Muscle Stem Cells and their Environment with Aging (3) 205–217
 Topaloglu, H., see Ceyhan-Birsoy, O. (1) 87–92
 Torbergsen, T., see Ørstavik, K. (2) 181–184
 Toutain, A., see Nelson, I. (3) 229–240
 Tran, T., see Lowe, J. (3) 257–268
 Trenell, M.I., see Newman, J. (2) 151–155
 Trollet, C., see Richard, P. (2) 175–180
 Turnbull, D.M., see Newman, J. (2) 151–155
- Urtizberea, J.A., see Cerino, M. (2) 131–136
- van den Berg, L., see Galban-Horcajo, F. (2) 157–165
 van den Engel-Hoek, L., I.J.M. de Groot, B.J.M. de Swart and C.E. Erasmus, Feeding and Swallowing Disorders in Pediatric Neuromuscular Diseases: An Overview (4) 357–369
 van der Maarel, S., see Statland, J.M. (3) 291–299
 van der Pol, W-L., see Galban-Horcajo, F. (2) 157–165
 van Engelen, B.G.M., see Deenen, J.C.W. (1) 73–85
 Vanhulle, C., see Servais, L. (3) 269–279
 Vaugier, I., see Catteruccia, M. (4) 453–462
 Verbeek, A.L.M., see Deenen, J.C.W. (1) 73–85
 Verschuuren, J.J.G.M., see Deenen, J.C.W. (1) 73–85
 Vest, K.E., L.H. Apponi, A. Banerjee, G.K. Pavlath and A.H. Corbett, An Antibody to Detect Alanine-Expanded PABPN1: A New Tool to Study Oculopharyngeal Muscular Dystrophy (4) 439–446
 Viollet, L., see Catteruccia, M. (4) 453–462
 Vissing, J., see Werlauff, U. (2) 167–174
 Vlam, L., see Galban-Horcajo, F. (2) 157–165
 Voit, T., see Servais, L. (3) 269–279
 Vuillaumier-Barrot, S., see Bouchet-Séraphin, C. (1) 27–38
 Vuillerot, C., see Catteruccia, M. (4) 453–462
- Wagner, K.R., see Moyer, A.L. (4) 371–385
 Wallace, S.C., see Ørstavik, K. (2) 181–184
 Wallgren-Pettersson, C., see Kiiski, K. (4) 433–438
 Watson, S., see Gardner, B.B. (1) 39–49
 Wehr, A., see Rensch, S.R. (2) 119–130
 Wei, Y., K. Speechley and C. Campbell, Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy: A Review (3) 313–324
 Wein, N., see Barthélémy, F. (3) 281–290

- Werlauff, U., H. Petri, N. Witting and J. Vissing, Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years (2) 167–174
- Wesolowska, M., G.S. Gorman, C.L. Alston, A. Pajak, A. Pyle, L. He, H. Griffin, P.F. Chinnery, J.A.L. Miller, A.M. Schaefer, R.W. Taylor, R.N. Lightowers and Z.M. Chrzanowska-Lightowers, Adult Onset Leigh Syndrome in the Intensive Care Setting: A Novel Presentation of a *C12orf65* Related Mitochondrial Disease (4) 409–419
- Willison, H., see Delmont, E. (2) 107–112
- Willison, H.J., see Galban-Horcajo, F. (2) 157–165
- Willmann, R., A. De Luca, K. Nagaraju and M.A. Rüegg, Best Practices and Standard Protocols as a Tool to Enhance Translation for Neuromuscular Disorders (2) 113–117
- Witting, N., see Werlauff, U. (2) 167–174
- Wodarczyk, A.J., see Lowe, J. (3) 257–268
- Wong, B., see Liu, D.Z. (4) 387–396
- Workman, E., see Rensch, S.R. (2) 119–130
- Wozny, A.S., see Cacheux, M. (4) 421–432
- Yao, G., see Hakim, C.H. (4) 397–407
- Yaou, R.B., see Nelson, I. (3) 229–240
- Yaou, R.B., see Servais, L. (3) 269–279
- Zaharieva, I., see Kiiski, K. (4) 433–438
- Zehrouni, K., see Servais, L. (3) 269–279
- Zhan, X., see Liu, D.Z. (4) 387–396